Personalis (PSNL) Expected to Post Quarterly Earnings on Tuesday

Personalis (NASDAQ:PSNL) is projected to announce its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Personalis to post earnings of ($0.2633) per share and revenue of $21.54 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 5:00 PM ET.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. The company had revenue of $22.36 million during the quarter, compared to analysts’ expectations of $16.69 million.

Personalis Price Performance

Shares of PSNL stock opened at $15.88 on Tuesday. The company’s fifty day moving average price is $16.27 and its two-hundred day moving average price is $11.17. The firm has a market capitalization of $1.66 billion, a P/E ratio of -14.57 and a beta of 2.32. Personalis has a 12 month low of $4.95 and a 12 month high of $18.89.

Insider Buying and Selling

In other news, CEO Christopher M. Hall sold 7,459 shares of the company’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $16.22, for a total transaction of $120,984.98. Following the completion of the transaction, the chief executive officer directly owned 228,527 shares of the company’s stock, valued at $3,706,707.94. This represents a 3.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Stephen Moore sold 2,068 shares of the firm’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $16.22, for a total transaction of $33,542.96. Following the completion of the transaction, the senior vice president directly owned 90,257 shares of the company’s stock, valued at approximately $1,463,968.54. This trade represents a 2.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,456 shares of company stock valued at $266,916 over the last 90 days. 4.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. BTIG Research lowered shares of Personalis from a “buy” rating to a “neutral” rating in a research report on Tuesday, October 6th. TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday, July 15th. Morgan Stanley lifted their target price on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Thursday, October 15th. Finally, Lake Street Capital lowered shares of Personalis from a “buy” rating to a “hold” rating and set a $16.25 price target for the company. in a research note on Monday, July 20th. Three analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $14.54.

About Personalis

Personalis, Inc is a genomics company focused on applying advanced sequencing and bioinformatics to cancer research and precision medicine. The company develops tests and data platforms designed to help researchers and clinicians characterize tumors, monitor disease, and support the development of targeted therapies.

Its product portfolio includes the NeXT Platform, which analyzes tumor and normal DNA and RNA to provide a detailed view of cancer biology, as well as products such as NeXT Dx, NeXT Liquid Biopsy, and NeXT Personal.